ERLOTINIB
erlotinib 100 mg tablet, 30
ERLOTINIB (10019H)
10019H
Manner of administration:Oral
Restriction 4600
Indication: Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer
(NSCLC)
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 30 | # of repeats: 3 | DPMQ: $437.35 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
|
|
|||||
|
|
|||||